Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ALNY | 8-K | bearish | 7/10 | Alnylam reported Q2 2026 non-GAAP diluted EPS of $1.84 (missed consensus of $2.15 by 14.5%) and total revenue of $1.291B | Jul 30, 2026 |
| LITS | 8-K | bullish | 6/10 | Lite Strategy announced it repurchased ~4.9 million shares (13% of outstanding) since December 2025 at an average price | Jul 30, 2026 |
| IRON | 8-K | bullish | 7/10 | Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share), slightly narrower than the $1.58 consensus. The key new | Jul 30, 2026 |
| AVXL | 8-K | neutral | 3/10 | Anavex reported preliminary Q2 fiscal 2026 results with a net loss of $5.3M ($0.06/share), narrowed from $11.2M ($0.13/s | Jul 30, 2026 |
| REGN | PRESS-RELEASE | bullish | 7/10 | Regeneron reported Q2 2026 non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, on total revenue of $4.29B (+17% | Jul 30, 2026 |
| AGIO | PRESS-RELEASE | bullish | 7/10 | Agios reported Q2 2026 revenue of $44.7M, up 259% YoY and 68% above consensus of $26.7M, driven by the AQVESME launch in | Jul 30, 2026 |
| AGIO | 8-K | bullish | 6/10 | Agios reported Q2 2026 revenue of $44.7M (up 259% YoY, 68% above consensus), driven by the AQVESME launch in thalassemia | Jul 30, 2026 |
| PVLA | PRESS-RELEASE | neutral | 2/10 | Palvella Therapeutics announced that its Chief Scientific Officer, Dr. Jeffrey Martini, has been selected to provide pub | Jul 30, 2026 |
| PHAT | PRESS-RELEASE | bearish | 6/10 | Phathom reported Q2 2026 net revenue of $74.3M, up 88% YoY and above the $72.7M consensus, driven by strong VOQUEZNA pre | Jul 30, 2026 |
| REGN | 8-K | bullish | 7/10 | Regeneron reported Q2 2026 revenue of $4.29B (+17% YoY) and non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, | Jul 30, 2026 |
| QNTM | PRESS-RELEASE | neutral | 3/10 | Quantum BioPharma settled CAD$123,487.43 in debt by issuing 30,948 Class B shares at CAD$3.99 per share to arm's length | Jul 30, 2026 |
| ADPT | INST-CLUSTER | bearish | 4/10 | Institutional 13F data for Q2 2026 shows a bearish cluster in Adaptive Biotechnologies, with 3 small asset managers trim | Jul 29, 2026 |
| GLSI | INSIDER-BUY | bullish | 5/10 | Greenwich LifeSciences CEO/CFO Snehal Patel made three open-market purchases totaling $67K over a week, increasing his s | Jul 29, 2026 |
| LQDA | CLUSTER | neutral | 3/10 | Two Liquidia Corp insiders, Director Stephen Bloch and Chief Business Officer Jason Adair, sold a combined $387K in open | Jul 29, 2026 |
| SCTX | CLUSTER | bullish | 8/10 | A massive insider buying cluster at Scribe Therapeutics: six insiders (including directors OrbiMed, Carl Gordon, and Beh | Jul 29, 2026 |
| MEDP | CLUSTER | neutral | 2/10 | CEO and EVP of Operations at Medpace sold a combined $6.61M in open-market sales over two days at ~$600/share. The CEO s | Jul 29, 2026 |
| VYNE | 3 | neutral | 2/10 | Steven Hoerter filed a Form 3 initial statement of beneficial ownership after Yarrow Bioscience (formerly VYNE Therapeut | Jul 29, 2026 |
| INO | PRESS-RELEASE | bearish | 7/10 | Inovio Pharmaceuticals priced a $20M underwritten public offering of 21,052,632 shares and warrants to purchase up to 42 | Jul 29, 2026 |
| VKTX | CLUSTER | neutral | 3/10 | VKTX CFO and COO sold a combined $1.32M in open-market sales on July 29, 2026, at ~$33.47/share, following non-cash stoc | Jul 29, 2026 |
| TOI | INSIDER-BUY | neutral | 2/10 | Jorey Chernett, a 10% owner of Oncology Institute, purchased 18,000 shares at $5.27 for $95,000 on July 21, 2026. The pu | Jul 29, 2026 |
| SCTX | CLUSTER | bullish | 8/10 | A massive insider buying cluster at Scribe Therapeutics, with three directors and two C-suite officers purchasing a tota | Jul 29, 2026 |
| NXTC | INSIDER-BUY | neutral | 4/10 | ADAR1 Capital Management, a 10% owner of NextCure, purchased $88K worth of NXTC shares across four open-market transacti | Jul 29, 2026 |
| HURA | 8-K | neutral | 3/10 | TuHURA Biosciences drew an additional $1.5 million under its existing $50 million revolving credit facility with Parkvie | Jul 29, 2026 |
| KURA | 8-K | neutral | 2/10 | Kura Oncology entered amended executive employment agreements with its CEO, CCO, and COO modifying severance provisions. | Jul 29, 2026 |
| BNTX | 6-K | neutral | 4/10 | BioNTech (BNTX) announced via 6-K that the European Commission has granted marketing authorization for its 2026-2027 COV | Jul 29, 2026 |
| NVS | COURT-RULING | neutral | 1/10 | A federal district court in the Northern District of California issued a routine order granting pro hac vice admission f | Jul 29, 2026 |
| NVO | COURT-RULING | bearish | 5/10 | The District of New Jersey partially denied Novo Nordisk's motion to dismiss a securities class action, allowing claims | Jul 29, 2026 |
| OSTX | 8-K | bullish | 6/10 | OS Therapies voluntarily terminated its $18M At Market Issuance Sales Agreement with B. Riley and JonesTrading, effectiv | Jul 29, 2026 |
| VNDA | PRESS-RELEASE | neutral | 1/10 | Vanda Pharmaceuticals Inc. announced it will report its Q2 2026 results on August 5, 2026. | Jul 29, 2026 |
| DYN | PRESS-RELEASE | bullish | 7/10 | Dyne Therapeutics reported Q2 2026 net loss of $1.08 per share, slightly narrower than the $0.97 loss in Q2 2025 but abo | Jul 29, 2026 |